TRIlogy-4

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody

  • 200091

Sorting 16 by

Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
  • Accepting patients
Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Mount Sinai
Blavatnik Family Chelsea Medical Center
New York, NY
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 864-8426

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.